Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial
Hubert H. Fernandez, Daniel Weintraub, Eric A. Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie L. Eberling, Aleksandar Videnović, Christopher Kenney
Topics & Concepts
TolerabilityClinical Global ImpressionPlaceboDementiaPsychologyRandomized controlled trialDiscontinuationInternal medicineMedicineAdverse effectPsychiatryDiseaseAlternative medicinePathologyParkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchNeurotransmitter Receptor Influence on Behavior